HIM
ARQT icon

Hillsdale Investment Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Hillsdale Investment Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-188,220
Closed -$4.43M – 656
2026
Q1 		$4.43M Buy
188,220
+8,800
+5% +$225K 0.12% 217
2025
Q4 		$5.21M Buy
+179,420
New +$4.59M 0.14% 192

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Hillsdale Investment Management's ARQT Position: Q2 2026 in Review

Hillsdale Investment Management sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 188,220 shares — an estimated $4.43M sold.

Hillsdale Investment Management first reported a position in ARQT in Q4 2025 and held it in 2 quarters. The position peaked at $5.21M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Hillsdale Investment Management reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Hillsdale Investment Management sold 188,220 Arcutis Biotherapeutics shares in Q2 2026, an estimated $4.43M.
  • Hillsdale Investment Management first reported a position in Arcutis Biotherapeutics in Q4 2025 and held it in 2 quarters.
  • Hillsdale Investment Management's Arcutis Biotherapeutics position peaked at $5.21M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.